METHYS Dx develops liquid biopsy tests that utilize ultra-sensitive detection of methylation markers in blood samples to analyze circulating tumor DNA. These tests enable early detection of cancer recurrences and provide dynamic monitoring of tumor progression, improving patient outcomes in oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Monitoring cancer recurrence and progression often relies on invasive biopsies and imaging techniques, which can be costly, time-consuming, and pose risks to patients. Traditional methods may also lack the sensitivity needed for early detection of minimal residual disease.
Solution
METHYS Dx develops liquid biopsy tests that use methylation markers to analyze circulating tumor DNA (ctDNA) from blood samples, providing a non-invasive method for cancer monitoring. The tests employ ultra-sensitive detection technology to identify unique molecular signatures specific to different cancers. By analyzing methylation patterns, the tests can establish a prognosis, track tumor evolution, and detect recurrences earlier than traditional methods. The liquid biopsy approach enables dynamic patient monitoring, offering a more comprehensive view of the clinical reality of the disease.
Target Audience
The primary users are oncologists and pathologists requiring accurate and timely monitoring of cancer progression and recurrence, as well as clinical laboratories seeking advanced diagnostic tools.
Features
- Liquid biopsy tests based on the analysis of circulating tumor DNA (ctDNA) in blood samples
- Detection of methylation markers for cancer-specific molecular signatures
- Ultrasensitive detection technology for early detection of minimal residual disease
- Prognostic assessment and monitoring of tumor evolution
- Non-invasive method for dynamic patient monitoring
- Potential to be used as a control for results obtained by sequencing or digital PCR technologies
- Alternative to NGS tests